RILUTEK IN SLOWING PROGRESSION OF FTD

RILUTEK 减缓 FTD 的进展

• 批准号: 6219948
• 负责人: Bruce Lee Miller
• 金额: $ 0.1万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6219948
• 关键词: clinical research; clinical trials; dementia; drug screening /evaluation; electromyography; human middle age (35-64); human old age (65+); human subject; human therapy evaluation; magnetic resonance imaging; mental disorder chemotherapy; neuropharmacologic agent; psychological tests; single photon emission computed tomography

To investigate the medicine Rilutek as a possible treatment for Frontotemporal Dementia. Rilutek is currently approved by the FDA for treatment of amyotrophic Lateral Sclerosis. FTD is a cortical degenerative disorder that often occurs in association with ALS. The relationship between ALS and FTD is unexplained but needs further study. Patients with FTD between the ages of 40 and 90 years of age, Patients will have their memory and thinking tested, will have an MRI, SPECT and EMG performed and will have blood drawn at every visit to monitor any adverse effects.

研究药物Rilutek可能是额颞痴呆的一种治疗方法。 Rilutek目前已获得FDA的批准，用于治疗肌萎缩性侧面硬化症。 FTD是一种经常与ALS相关的皮质变性疾病。 ALS与​​FTD之间的关系无法解释，但需要进一步研究。 FTD患者在40至90岁之间，患者的记忆力和思维测试，将进行MRI，SPECT和EMG进行，并在每次访问时都会抽血，以监测任何不良影响。